Detalles de la búsqueda
1.
Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer.
Cancer
; 126(22): 4847-4858, 2020 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780421
2.
Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 175(1): 265-266, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30632020
3.
Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Breast Cancer Res Treat
; 165(3): 573-583, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28664507
4.
Health economic impact of risk group selection according to ASCO-recommended biomarkers uPA/PAI-1 in node-negative primary breast cancer.
Breast Cancer Res Treat
; 138(3): 839-50, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23568480
5.
PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Trials
; 24(1): 338, 2023 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37198674
6.
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial.
JAMA Oncol
; 9(7): 946-954, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37166817
7.
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer.
J Clin Oncol
; 40(23): 2557-2567, 2022 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35404683
8.
Avoiding spam in the proteolytic internet: future strategies for anti-metastatic MMP inhibition.
Biochim Biophys Acta
; 1803(1): 95-102, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19800374
9.
Phenotype Discordance between Primary Tumor and Metastasis Impacts Metastasis Site and Outcome: Results of WSG-DETECT-PriMet.
Breast Care (Basel)
; 16(5): 475-483, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34720807
10.
Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients.
Breast Care (Basel)
; 16(1): 50-58, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33716632
11.
The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Ther Adv Med Oncol
; 12: 1758835920973130, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33281950
12.
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
J Clin Oncol
; 37(10): 799-808, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785826
13.
Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer.
Clin Cancer Res
; 13(4): 1123-32, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317820
14.
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer Res
; 62(16): 4617-22, 2002 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12183417
15.
West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.
J Clin Oncol
; 34(20): 2341-9, 2016 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926676
16.
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
J Clin Oncol
; 20(4): 1000-7, 2002 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11844823
17.
Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
J Clin Oncol
; 21(6): 1022-8, 2003 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-12637466
18.
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Thromb Haemost
; 91(3): 450-6, 2004 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-14983219
19.
Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts.
Clin Breast Cancer
; 3(3): 196-200, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12196277
20.
PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs.
Onco Targets Ther
; 7: 1723-31, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25336969